Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 21:2019:18-0150.
doi: 10.1530/EDM-18-0150. Online ahead of print.

Cushing syndrome: uncovering Carney complex due to novel PRKAR1A mutation

Affiliations

Cushing syndrome: uncovering Carney complex due to novel PRKAR1A mutation

Catherine D Zhang et al. Endocrinol Diabetes Metab Case Rep. .

Abstract

Carney complex (CNC) is a rare multiple neoplasia syndrome characterized by spotty pigmentation of the skin and mucosa in association with various non-endocrine and endocrine tumors, including primary pigmented nodular adrenocortical disease (PPNAD). A 20-year-old woman was referred for suspected Cushing syndrome. She had signs of cortisol excess as well as skin lentigines on physical examination. Biochemical investigation was suggestive of corticotropin (ACTH)-independent Cushing syndrome. Unenhanced computed tomography scan of the abdomen did not reveal an obvious adrenal mass. She subsequently underwent bilateral laparoscopic adrenalectomy, and histopathology was consistent with PPNAD. Genetic testing revealed a novel frameshift pathogenic variant c.488delC/p.Thr163MetfsX2 (ClinVar Variation ID: 424516) in the PRKAR1A gene, consistent with clinical suspicion for CNC. Evaluation for other clinical features of the complex was unrevealing. We present a case of PPNAD-associated Cushing syndrome leading to the diagnosis of CNC due to a novel PRKAR1A pathogenic variant. Learning points: PPNAD should be considered in the differential for ACTH-independent Cushing syndrome, especially when adrenal imaging appears normal. The diagnosis of PPNAD should prompt screening for CNC. CNC is a rare multiple neoplasia syndrome caused by inactivating pathogenic variants in the PRKAR1A gene. Timely diagnosis of CNC and careful surveillance can help prevent potentially fatal complications of the disease.

Keywords: 2019; ACTH; Adolescent/young adult; Adrenal; Adrenalectomy; Anxiety; Buffalo hump; CT scan; Carney complex; Cortisol; Cortisol (serum); Cushing's syndrome; DNA sequencing; Dehydroepiandrostenedione; Dexamethasone suppression (high dose); Dexamethasone suppression (low dose); Error in diagnosis/pitfalls and caveats; Facial plethora; Facies - moon; Female; Fludrocortisone; Genetics; Glucocorticoids; Haematoxylin and eosin staining; Hirsutism; Histopathology; Hydrocortisone; Laparoscopic adrenalectomy; March; Mineralocorticoids; Molecular genetic analysis; Necrosis; Obesity; Skin pigmentation - spotty; Striae; United States; Weight gain; White.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Skin examination was notable for lentigines on the lips (A) and a café-au-lait spot on the neck (B).
Figure 2
Figure 2
Bilateral adrenal glands (arrows) appeared normal on computed tomography without significant hyperplasia or obvious adrenal nodules.
Figure 3
Figure 3
Gross examination showed left (A) – 5.1 g, 4.7 × 3.2 × 1.2 cm – and right (B) – 5.0 g, 4.5 × 3.0 × 1.5 cm – adrenal glands within normal weight and size. Multiple tan-brown nodules were seen on the capsule and within the cortex on cross-sectioning (C and D).
Figure 4
Figure 4
Adrenal histology with hematoxylin and eosin stain: objective magnification ×4 (A) and ×10 (B). Well-circumcised nodules are seen containing brown pigment and cells with round-to-oval nuclei and eosinophilic cytoplasm.
Figure 5
Figure 5
Gene sequencing revealed a novel pathogenic variation in the PRKAR1A gene. Deletion of the cytosine base (c.488delC) changes codon Threonine 163 to a Methionine residue and creates a premature Stop codon at position 2 of the new reading frame (p.THr163MetfsX2).

Similar articles

Cited by

References

    1. Correa R, Salpea P, Stratakis CA. Carney complex: an update. European Journal of Endocrinology 2015. 173 M85–M97. (10.1530/EJE-15-0209) - DOI - PMC - PubMed
    1. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine 1985. 64 270–283. (10.1097/00005792-198507000-00007) - DOI - PubMed
    1. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, Rene-Corail F, Stergiopoulos S, Bourdeau I, et al Mutations in regulatory subunit type 1A of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1a): phenotype analysis on 353 patients and 80 different genotypes. Journal of Clinical Endocrinology and Metabolism 2009. 94 2085–2091. (10.1210/jc.2008-2333) - DOI - PMC - PubMed
    1. Courcoutsakis NA, Tatsi C, Patronas NJ, Lee CC, Prassopoulos PK, Stratakis CA. The complex of myxomas, spotty skin pigmentation and endocrine overactivity (Carney complex): imaging findings with clinical and pathological correlation. Insights into Imaging 2013. 4 119–133. (10.1007/s13244-012-0208-6) - DOI - PMC - PubMed
    1. Stratakis CA, Sarlis N, Kirschner LS, Carney JA, Doppman JL, Nieman LK, Chrousos GP, Papanicolaou DA. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Annals of Internal Medicine 1999. 131 585–591. (10.7326/0003-4819-131-8-199910190-00006) - DOI - PubMed

LinkOut - more resources